Navigation Links
NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
Date:7/22/2008

SOPHIA ANTIPOLIS, France, July 22 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced it has successfully completed the enrollment of 417 osteoarthritis (OA) patients with controlled hypertension in two clinical pharmacology studies in the United States, in line with previously announced timelines. These trials are designed to assess the blood pressure profile of naproxcinod, in comparison to ibuprofen and naproxen, using the Ambulatory Blood Pressure Monitoring (ABPM) technique. Results of both studies are expected in Q4 2008. Naproxcinod is NicOx' lead investigational drug and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is currently in phase 3 clinical development for the treatment of the signs and symptoms of OA, with results of the last two phase 3 studies anticipated in the second half of 2008.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen and naproxen, are commonly used by OA patients to control their chronic pain, inflammation and stiffness. However, these important products have the tendency to raise blood pressure, a side effect of particular concern in OA patients due to the high prevalence of hypertension and other cardiovascular risk factors in this elderly population.

The objectives of these phase 1 ABPM trials, known as the 111 and 112 studies, are to provide important additional data on the 24-hour blood pressure profile of naproxcinod in chronically treated OA patients with controlled hypertension, in comparison to commonly used NSAIDs. The 111 is a 12-week study, which has enrolled 118 patients at 30 clinical sites, who are receiving increasing doses of either naproxcinod or naproxen at three week intervals. The 112 study has enrolled 299 patients at 60 clinical sites, which have been randomized to five groups, receiving 13 weeks of treatment with: naproxcinod 375 mg bid (twice daily), naproxcinod 750 mg bid,
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
5. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
6. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
7. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
8. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
11. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... LONDON , July 11, 2014 ... ended at 4,396.20, down 0.52%, the Dow Jones Industrial Average ... 500 closed at 1,964.68, down 0.41%. The losses were broad ... in negative. The S&P 500 Health Care Sector Index ended ... advanced 2.75% in the last one month. Investor-Edge has initiated ...
(Date:7/11/2014)... According to a new market ... (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - Global ... the global endoscopy devices market was valued at USD ... at a CAGR of 6.8% from 2013 to 2019, ... in 2019. Browse the full Endoscopy Devices Market ...
(Date:7/11/2014)... , July 11, 2014 Research ... addition of the "Immunoprotein Diagnostic Testing Market ... the highest CAGR of 6% and is expected ... report to their offering. ... immunoprotein diagnostic testing has been segmented according to ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... Inc. (Nasdaq: CALP ) will conduct a ... results at 9:00 a.m. ET on Thursday, October 28. ... McAree, Chief Financial Officer, will host the call. Management ... outlook for the future. A news ...
... Oct. 14 OrthoAccel Technologies, Inc., developers of ... to enhance orthodontics, announced this week that it ... its Corporate Board.  Mr. Cooper,s directorship will involve ... strategy, with a focus on market growth. ...
Cached Medicine Technology:Caliper Life Sciences' Third Quarter 2010 Financial Results Conference Call Notice 2Medical Device Industry Executive Joins OrthoAccel Technologies, Inc. Board of Directors 2Medical Device Industry Executive Joins OrthoAccel Technologies, Inc. Board of Directors 3
(Date:7/11/2014)... As reported by Forbes in the article Robert ... Blame (6/30), Indino Downey has reportedly been arrested after ... it with. His father, well-known actor Robert Downey Jr. ... him may have something to do with his addiction ... 1980s and 1990s for substance abuse before finally getting ...
(Date:7/11/2014)... Los Angeles, CA (PRWEB) July 11, 2014 ... Kevin Sands today announces that he uses mini and ... these treatments offer the defining feature that distinguishes dental ... of teeth in addition to the crowns. This alone ... dental implants also offer advantages related to comfort, ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- Polio is history ... places like Afghanistan, Nigeria and Pakistan. Giving vaccinated children ... their immunity and help eradicate the highly infectious disease, ... is highly effective, immunity wanes as early as a ... be infected and contribute to the spread of the ...
(Date:7/11/2014)... breast cancer patients, the era of personalized medicine may ... by USC Stem Cell researcher Min Yu and scientists ... In a July 11 study in Science , ... cancer cells circulating through the blood streams of six ... "seeds" of metastasis, which travel to and establish secondary ...
(Date:7/11/2014)... American Farmer is proud to announce their latest ... at 8:30 am ET. , In this episode, American ... designed and formulated for use on a wide range ... help the crop realize its maximum genetic yield potential ... The show also features UniSouth Genetics, a non-profit co-op ...
Breaking Medicine News(10 mins):Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Dental Implant Dentist, Kevin Sands DDS, Now Uses Mini and Full Mouth Implants to Replace Missing Teeth 2Health News:Researchers Assess New Way to Boost Polio Immunity 2Health News:New Episode of American Farmer Featuring Sunbelt, UniSouth Genetics, and Michigan Milk Producers Association Airing on RFD-TV 2
... 2008-2009 Term, FREDERICK, Md., April 8, 2008 ... and management,consulting firm, was recently elected as President of ... Association (HCAA). He,will begin his one-year term in October ... for facilitating the,transition of a new management company. Bastis ...
... April 8, 2008 CryoLife, Inc. (NYSE:,CRY) ... company,announced today that William F. Northrup, III, ... medical relations and education, reporting to Steven ... newly created position, Dr. Northrup, a board-certified,cardiovascular ...
... Work, Stability Characterization of Dry-Patch ... Vaccine ... ) today announced it will receive a,cost-reimbursement grant for up to $943,856 ... work on a,patch-based version of the anthrax vaccine., Under the 1-year ...
... employees, CHARLOTTESVILLE, Va., April 8, 2008 ... launched a,new online training module for their CareTracker ... of employees on the use of CareTracker., ... as Silverchair,s,eLearning system for senior care facilities: the ...
... will test effectiveness of health,management programs to ... in the,Medicare population, MINNEAPOLIS, April 8, ... today it is working with Pfizer Health,Solutions ... as part of a,three-year Senior Risk Reduction ...
... Commences for Issuance of Certification to Operate HMO, ... Group, Inc. (Phyhealth) (Pink Sheets: PHYH), a developer ... announced that all applications for the launch of ... been filed and accepted for review by the ...
Cached Medicine News:Health News:Brian Bastis Elected as National CPA Health Care Advisors Association Executive Committee President 2Health News:William F. Northrup, III, M.D. Joins CryoLife as Vice President of Medical Relations and Education 2Health News:William F. Northrup, III, M.D. Joins CryoLife as Vice President of Medical Relations and Education 3Health News:Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine 2Health News:Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine 3Health News:Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine 4Health News:Resource Systems and Silverchair Learning Systems Launch CareTracker Online Training Module 2Health News:HealthFitness Teams with Pfizer Health Solutions to Implement CMS Senior Risk Reduction Demonstration Project 2Health News:HealthFitness Teams with Pfizer Health Solutions to Implement CMS Senior Risk Reduction Demonstration Project 3Health News:HealthFitness Teams with Pfizer Health Solutions to Implement CMS Senior Risk Reduction Demonstration Project 4Health News:Phyhealth HMO Applications Accepted by All Required Federal and State Agencies 2
... Plate is a semi-rigid system intended ... The Slim-LOC is based on the ... current market technology. The Slim-LOCTM system ... instrumentation. Reduced width (16 mm), low ...
... SC-Acufix anterior cervical plate system is a ... integrated swivel, which provides for consistent, reliable ... bone screw disengagement or backout. This innovative ... locking screw. Simply implant your screws and ...
... a leading provider of telemedicine solutions. ... state-of-the-art technology deliver accurate, reliable and ... professionals and clients in improving outcomes. ... ECG technology to gather patient data, ...
... is a high performance temperature controlled shaker ... shaking speed and incubation time are fully ... parameters are displayed on the LCD in ... below the microplates provide uniform incubation with ...
Medicine Products: